



Zeposia in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

NEUROLOGY · RELAPSING MS & ULCERATIVE COLITIS

The clinical situation

Zeposia (ozanimod) is an oral S1P1/S1P5 receptor modulator FDA-approved for relapsing multiple sclerosis and moderately-to-severely active ulcerative colitis. Manufactured by Bristol Myers Squibb. A 7-day titration pack is used at initiation (stepping to 0.92 mg daily maintenance) to manage the first-dose cardiac-conduction signal. Pre-treatment workup covers baseline ECG, cardiac history, CBC with absolute lymphocyte count, LFTs, varicella serology, and ophthalmologic/dermatologic baseline per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist or gastroenterologist documents MS subtype or UC severity, prior therapies, and Zeposia rationale.
- 2 Baseline workup.** ECG, cardiac review, CBC with lymphocyte count, LFTs, ophthalmology baseline, varicella serology, dermatology review.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, titration plan, and chain-of-custody commitment; DHA/DoH approvals align where applicable.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the 7-day starter pack; first-dose cardiac monitoring arranged per protocol.

Indicative economics

Reference US cash-pay range: USD 96,000–115,000 per year of Zeposia (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Bristol Myers Squibb authorised distribution.

Documentation. Physician kit tailored to MoHAP / DHA / DoH review, with S1P-modulator class safety annex. **Logistics.**

Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through titration and monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Zeposia × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/zeposia-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team